Bernd Schmidt
Chief Tech/Sci/R&D Officer bij SENSORION
Profiel
Bernd Schmidt is currently the Chief Technical Officer at Sensorion SA since 2023.
Prior to this, he worked as the Vice President-Product Delivery at Quell Therapeutics Ltd.
Mr. Schmidt is a graduate of Friedrich-Alexander University of Erlangen-Nuremberg.
Actieve functies van Bernd Schmidt
Bedrijven | Functie | Begin |
---|---|---|
SENSORION | Chief Tech/Sci/R&D Officer | 11-12-2023 |
Eerdere bekende functies van Bernd Schmidt
Bedrijven | Functie | Einde |
---|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van Bernd Schmidt
Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SENSORION | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |